Sorafenib (BAY 43-9006) slows cell cycle progression, is a TRAIL sensitizer,but is not a radiosensitizer

被引：0
|
作者：
Plastaras, John P.
Soto, Nanette M.
Dicker, David T.
Flaherty, Keith T.
Smith, Charles D.
El-Deiry, Wafik S.
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
[3] Penn State Coll Med, Hershey, PA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3828
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized discontinuation trial of sorafenib (BAY 43-9006)
    Jain, Lokesh
    Venitz, Juergen
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2006, 5 (10) : 1270 - 1272
  • [2] Sorafenib (BAY 43-9006): Review of Clinical Development
    Ng, Raymond
    Chen, Eric X.
    CURRENT CLINICAL PHARMACOLOGY, 2006, 1 (03): : 223 - 228
  • [3] BAY 43-9006: Preclinical data
    Wilhelm, S
    Chien, DS
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (25) : 2255 - 2257
  • [4] A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma
    Uldrick, Thomas S.
    Goncalves, Priscila H.
    Wyvill, Kathleen M.
    Peer, Cody J.
    Bernstein, Wendy
    Aleman, Karen
    Polizzotto, Mark N.
    Venzon, David
    Steinberg, Seth M.
    Marshall, Vickie
    Whitby, Denise
    Little, Richard F.
    Wright, John J.
    Rudek, Michelle A.
    Figg, William D.
    Yarchoan, Robert
    ONCOLOGIST, 2017, 22 (05): : 505 - +
  • [5] Sorafenib (BAY 43-9006) inhibits imatinib-resistant mutant KIT signaling
    Gedrich, R.
    Sullivan, E.
    Shi, H.
    Brown, M.
    Rocks, S.
    Burd, A.
    Liu, L.
    Wilhelm, S.
    EJC SUPPLEMENTS, 2006, 4 (12): : 173 - 173
  • [6] Mechanisms of hypertension associated with BAY 43-9006
    Veronese, ML
    Mosenkis, A
    Flaherty, KT
    Gallagher, M
    Stevenson, JP
    Townsend, RR
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1363 - 1369
  • [7] Sorafenib (BAY 43-9006) protects normal murine gut from radiation damage
    Herrera, F. G.
    Lunt, S. J.
    Fyles, A.
    Milosevic, M.
    Supiot, S.
    Ran, J.
    Zhao, H.
    Bristow, R.
    Hill, R. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S125 - S125
  • [8] Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307
    Janne, Pasi A.
    Wang, Xiaofei F.
    Krug, Lee M.
    Hodgson, Lydia
    Vokes, Everett E.
    Kindler, Hedy L.
    ANNALS OF ONCOLOGY, 2006, 17 : 216 - 217
  • [9] Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
    Ranieri, G.
    Gadaleta-Caldarola, G.
    Goffredo, V.
    Patruno, R.
    Mangia, A.
    Rizzo, A.
    Sciorsci, R. L.
    Gadaleta, C. D.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (07) : 938 - 944
  • [10] Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma:: CALGB 30307
    Janne, P. A.
    Wang, X. F.
    Krug, L. M.
    Hodgson, L.
    Vokes, E. E.
    Kindler, H. L.
    LUNG CANCER, 2006, 54 : S51 - S52
12345